Global Acute Bacterial Skin And Skin Structure Infections Market Size study, by Type of Infection, Route of Administration, Distribution Channel, and Regional Forecasts 2022-2032

Description

Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market is valued approximately at USD 1.28 billion in 2023 and is anticipated to grow with a steady CAGR of more than 4.84% over the forecast period 2024-2032. ABSSSI includes a broad category of skin infections caused predominantly by gram-positive pathogens such as Staphylococcus aureus (including MRSA) and Streptococcus species. These infections, often resulting from trauma, post-surgical complications, or chronic wounds, demand swift intervention due to their rapid progression and high risk of systemic complications. The growing resistance to first-line antibiotics and an increasing aging population with comorbidities have significantly heightened the need for effective ABSSSI-targeted therapeutics with improved safety profiles and faster treatment timelines.

This clinical urgency has driven pharmaceutical companies to accelerate research on novel agents, combination therapies, and new-generation antibiotics that offer both bactericidal efficacy and low toxicity. The adoption of long-acting injectables and once-daily IV/oral options are gaining traction due to their compatibility with outpatient care models and reduced hospitalization burdens. Moreover, regulatory incentives for antimicrobial development, such as the GAIN (Generating Antibiotic Incentives Now) Act in the U.S., are encouraging market participants to bring innovative ABSSSI drugs to market swiftly. Nonetheless, despite robust clinical development, issues around pricing, limited patent windows, and the threat of antimicrobial resistance still challenge market scalability.

Technological progress in pathogen-specific diagnostics is catalyzing precision-based treatment approaches, enabling faster identification of causative organisms and their resistance profiles. This not only shortens the diagnostic-to-treatment window but also aids in antibiotic stewardship by reducing empirical prescribing. Distribution models are also evolving, with hospital pharmacies dominating due to intravenous administration needs, while the emergence of oral formulations and telehealth-assisted prescriptions is opening pathways for retail and online pharmacies to expand their share.

Regionally, North America leads the ABSSSI market, fueled by strong hospital infrastructure, higher disease awareness, and favorable reimbursement frameworks. The U.S. remains the focal point, thanks to early access to breakthrough therapies and the presence of major industry players. Europe follows closely, driven by rising hospitalization rates and coordinated efforts to manage antibiotic resistance. The Asia Pacific region, meanwhile, is expected to witness the fastest growth, propelled by increasing healthcare spending, rising infection rates, and broader access to branded and generic antibiotics. In nations such as China and India, the push for healthcare infrastructure reform and national antibiotic policy frameworks are expected to further bolster market growth.

Major market player included in this report are:

Melinta Therapeutics Inc.
Pfizer Inc.
Merck & Co., Inc.
Paratek Pharmaceuticals, Inc.
Aurobindo Pharma Ltd.
GlaxoSmithKline plc
Wockhardt Ltd.
Dr. Reddy's Laboratories Ltd.
Shionogi & Co., Ltd.
Basilea Pharmaceutica Ltd.
Tetraphase Pharmaceuticals, Inc.
Venatorx Pharmaceuticals, Inc.
Entasis Therapeutics Inc.
Cipla Ltd.
Sandoz International GmbH

The detailed segments and sub-segment of the market are explained below:

By Type of Infection

Cellulitis
Wound Infection
Post-surgical Infection
Others

By Route of Administration

Oral
Injectable

By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
Rest of Europe
Asia Pacific
China
India
Japan
Australia
South Korea
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Years considered for the study are as follows:

Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with country-level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

Chapter 1. Global Acute Bacterial Skin And Skin Structure Infections Market Executive Summary

1.1. Global ABSSSI Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Type of Infection
- 1.3.2. By Route of Administration
- 1.3.3. By Distribution Channel
1.4. Key Trends
1.5. Reimbursement & Access Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global ABSSSI Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability of Novel Agents
  - 2.3.3.2. Manufacturing Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Competitive Landscape
  - 2.3.3.5. Economic Viability (Healthcare Payer Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Clinical Guidelines & Stewardship Programs
  - 2.3.4.2. Technological Advancements in Diagnostics
  - 2.3.4.3. Patient Awareness & Compliance
  - 2.3.4.4. Healthcare Access & Reimbursement
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global ABSSSI Market Dynamics

3.1. Market Drivers
- 3.1.1. Escalating Antimicrobial Resistance and High MRSA Prevalence
- 3.1.2. Regulatory Incentives (e.g., GAIN Act) Accelerating New Antibiotic Approvals
- 3.1.3. Shift Toward Outpatient Care Models and Long-acting Formulations
3.2. Market Challenges
- 3.2.1. Pricing Pressures and Limited Patent Lifecycles
- 3.2.2. Threat of Emerging Resistance Against Novel Agents
3.3. Market Opportunities
- 3.3.1. Growth of Precision Diagnostics Enabling Targeted Therapy
- 3.3.2. Expansion of Telehealth-Facilitated Oral Antibiotic Distribution
- 3.3.3. Fastest Growth in Asia Pacific Due to Healthcare Infrastructure Investment

Chapter 4. Global ABSSSI Market Industry Analysis

4.1. Porter's Five Forces Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economic
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspectives
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global ABSSSI Market Size & Forecasts by Type of Infection 2022-2032

5.1. Segment Dashboard
5.2. Global ABSSSI Market: Type of Infection Revenue Trend Analysis, 2022 & 2032 (USD Million)
- 5.2.1. Cellulitis
- 5.2.2. Wound Infections
- 5.2.3. Post-surgical Infections
- 5.2.4. Others

Chapter 6. Global ABSSSI Market Size & Forecasts by Route of Administration 2022-2032

6.1. Segment Dashboard
6.2. Global ABSSSI Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Million)
- 6.2.1. Oral
- 6.2.2. Injectable

Chapter 7. Global ABSSSI Market Size & Forecasts by Distribution Channel 2022-2032

7.1. Segment Dashboard
7.2. Global ABSSSI Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Million)
- 7.2.1. Hospital Pharmacy
- 7.2.2. Retail Pharmacy
- 7.2.3. Online Pharmacy

Chapter 8. Global ABSSSI Market Size & Forecasts by Region 2022-2032

8.1. North America ABSSSI Market
- 8.1.1. U.S. ABSSSI Market
  - 8.1.1.1. By Type of Infection Breakdown, 2022-2032
  - 8.1.1.2. By Route of Administration Breakdown, 2022-2032
- 8.1.2. Canada ABSSSI Market
8.2. Europe ABSSSI Market
- 8.2.1. UK ABSSSI Market
- 8.2.2. Germany ABSSSI Market
- 8.2.3. France ABSSSI Market
- 8.2.4. Spain ABSSSI Market
- 8.2.5. Italy ABSSSI Market
- 8.2.6. Rest of Europe ABSSSI Market
8.3. Asia Pacific ABSSSI Market
- 8.3.1. China ABSSSI Market
- 8.3.2. India ABSSSI Market
- 8.3.3. Japan ABSSSI Market
- 8.3.4. Australia ABSSSI Market
- 8.3.5. South Korea ABSSSI Market
- 8.3.6. Rest of Asia Pacific ABSSSI Market
8.4. Latin America ABSSSI Market
- 8.4.1. Brazil ABSSSI Market
- 8.4.2. Mexico ABSSSI Market
- 8.4.3. Rest of Latin America ABSSSI Market
8.5. Middle East & Africa ABSSSI Market
- 8.5.1. Saudi Arabia ABSSSI Market
- 8.5.2. South Africa ABSSSI Market
- 8.5.3. Rest of Middle East & Africa ABSSSI Market

Chapter 9. Competitive Intelligence

9.1. Key Company SWOT Analysis
- 9.1.1. Melinta Therapeutics Inc.
- 9.1.2. Pfizer Inc.
- 9.1.3. Merck & Co., Inc.
9.2. Top Market Strategies
9.3. Company Profiles
- 9.3.1. Melinta Therapeutics Inc.
  - 9.3.1.1. Key Information
  - 9.3.1.2. Overview
  - 9.3.1.3. Financial (Subject to Data Availability)
  - 9.3.1.4. Product Summary
  - 9.3.1.5. Market Strategies
- 9.3.2. Paratek Pharmaceuticals, Inc.
- 9.3.3. Aurobindo Pharma Ltd.
- 9.3.4. GlaxoSmithKline plc
- 9.3.5. Wockhardt Ltd.
- 9.3.6. Dr. Reddy's Laboratories Ltd.
- 9.3.7. Shionogi & Co., Ltd.
- 9.3.8. Basilea Pharmaceutica Ltd.
- 9.3.9. Tetraphase Pharmaceuticals, Inc.
- 9.3.10. Venatorx Pharmaceuticals, Inc.
- 9.3.11. Entasis Therapeutics Inc.
- 9.3.12. Cipla Ltd.
- 9.3.13. Sandoz International GmbH

Chapter 10. Research Process

10.1. Research Process
- 10.1.1. Data Mining
- 10.1.2. Analysis
- 10.1.3. Market Estimation
- 10.1.4. Validation
- 10.1.5. Publishing
10.2. Research Attributes